LFM-A13

• 产品号: L6920
• CAS号: 244240-24-2
• 分子式: C11H8Br2N2O2
• 分子量: 360.00142
• 纯 度: ≥98% (HPLC)

产品别名

• 标题: LFM-A13
• IUPAC标准名: 2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide
• IUPAC传统名: 2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide
• 别名: (2Z)-2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide; a-Cyano-b-hydroxy-b-methyl-N-(2,5-dibromophenyl)propenamide; α-Cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide

产品登记号

• MDL号: MFCD09878279
• CAS号: 244240-24-2

产品性质

• Empirical Formula (Hill Notation): C11H8Br2N2O2
• 纯度: ≥98% (HPLC)
• 外观: white to tan powder
• 溶解度: DMSO: ≥19 mg/mL
• GHS警示词: Warning
• GHS危险声明: H302-H312-H332
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• GHS警示性声明: P280
• 危险公开号: 20/21/22
• 安全公开号: 36/37
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Biochem/physiol Actions
LFM-A13 is an inhibitor of the nonreceptor tyrosine kinase Bruton′s tyrosine kinase (Btk), a new molecular target for treatment of B-cell lymphoma and autoimmune disorders. LFMA13 inhibited recombinant BTK with an IC50 value of 2.5microM with 100-fold lower inhibitory activity against a number of other protein kinases including JAK1, JAK2, EGFR, IRK, IKK, and CDK1, 2 and 3, as well as several other related kinases

详细说明 (简体中文)

Biochem/physiol Actions
LFM-A13 is an inhibitor of the nonreceptor tyrosine kinase Bruton′s tyrosine kinase (Btk), a new molecular target for treatment of B-cell lymphoma and autoimmune disorders. LFMA13 inhibited recombinant BTK with an IC50 value of 2.5microM with 100-fold lower inhibitory activity against a number of other protein kinases including JAK1, JAK2, EGFR, IRK, IKK, and CDK1, 2 and 3, as well as several other related kinases